LM-108 with sintilimab for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new antibody combination for non-small cell lung cancer that has spread or come back. It may help people whose cancer stopped responding to immunotherapy or who haven't had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or recurrent non-small cell lung cancer that can't be treated with surgery or curative radiation.
- Your cancer must not have certain gene mutations like EGFR or ALK.
- Either your cancer grew after at least 6 months on a PD-1 inhibitor (cohort 1), or you haven't had any systemic treatment for advanced cancer (cohort 2).
- You need to have at least one measurable tumor and be in generally good health (ECOG score 0 or 1).
- You must be willing to provide a tumor sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
This trial tests whether continuing a PD-1 inhibitor (a type of immunotherapy) after surgery can help people with non-small cell lung cancer who did not have a complete response to initial chemotherapy plus immunotherapy before surgery. It aims to improve outcomes for those whose tumors still had significant cancer cells after the first treatment.
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
Hear when a new PD-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.